Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (601-610 of 692) with videos related to

Pageof 70
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 10, 2022
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label studyDaniel S W Tan, Sang-We Kim, Santiago Ponce Aix, et al.
Plos One|May 16, 2018
The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trialGitta Kleijn, Birgit I Lissenberg-Witte, Ernst T Bohlmeijer, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJames Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
British Journal of Cancer|July 25, 2019
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 studyHarry J M Groen, Erik H F M van der Heijden, Theo J Klinkenberg, et al.
JAMA Oncology|June 4, 2023
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical TrialJulien Mazieres, Paul K Paik, Marina C Garassino, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trialEnriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2013
EGFR mutation analysis in sputum of lung cancer patients: a multitechnique studyA Jasmijn Hubers, Daniëlle A M Heideman, Yasushi Yatabe, et al.
JTO Clinical and Research Reports|March 29, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLCJudith L Gulikers, G D Marijn Veerman, Merel Jebbink, et al.
Lancet (London, England)|April 30, 2002
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trialHarm van Tinteren, Otto S Hoekstra, Egbert F Smit, et al.
Pageof 70

Showing results (601-610 of 692) with videos related to

Sort By:
Pageof 70
European Journal of Cancer (Oxford, England : 1990)|July 10, 2022
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label studyDaniel S W Tan, Sang-We Kim, Santiago Ponce Aix, et al.
Plos One|May 16, 2018
The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trialGitta Kleijn, Birgit I Lissenberg-Witte, Ernst T Bohlmeijer, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJames Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
British Journal of Cancer|July 25, 2019
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 studyHarry J M Groen, Erik H F M van der Heijden, Theo J Klinkenberg, et al.
JAMA Oncology|June 4, 2023
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical TrialJulien Mazieres, Paul K Paik, Marina C Garassino, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trialEnriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2013
EGFR mutation analysis in sputum of lung cancer patients: a multitechnique studyA Jasmijn Hubers, Daniëlle A M Heideman, Yasushi Yatabe, et al.
JTO Clinical and Research Reports|March 29, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLCJudith L Gulikers, G D Marijn Veerman, Merel Jebbink, et al.
Lancet (London, England)|April 30, 2002
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trialHarm van Tinteren, Otto S Hoekstra, Egbert F Smit, et al.
Pageof 70